glp-1 skin sensitivity RAs and Health: Exploring Dermatologic Side Effects and Therapeutic Interventions[v1] GLP-1RA & Inflammatory Skin Diseases
Description
N Engl J Med 2022;387(3):205216
![glp-1 skin sensitivity RAs and Health: Exploring Dermatologic Side Effects and Therapeutic Interventions[v1] GLP-1RA & Inflammatory Skin Diseases](https://www.usdermatologypartners.com/wp-content/uploads/2026/01/AdobeStock_256725929.jpg)
Novo Nordisk, a competitor to Eli Lilly, has already sought FDA approval for an oral semaglutide pill, its oral GLP-1 pill, and is expected to receive a decision by the end of this year
![glp-1 skin sensitivity RAs and Health: Exploring Dermatologic Side Effects and Therapeutic Interventions[v1] GLP-1RA & Inflammatory Skin Diseases](https://www.mdpi.com/jcm/jcm-15-02944/article_deploy/html/images/jcm-15-02944-g002-550.jpg)
How should I use Saxenda
![glp-1 skin sensitivity RAs and Health: Exploring Dermatologic Side Effects and Therapeutic Interventions[v1] GLP-1RA & Inflammatory Skin Diseases](https://www.primeskinlaser.com/wp-content/uploads/2024/10/semaglutide-info-desktop-1.jpg)
Building supply redundancy into travel plans transforms potential medication emergencies into minor inconveniences
![glp-1 skin sensitivity RAs and Health: Exploring Dermatologic Side Effects and Therapeutic Interventions[v1] GLP-1RA & Inflammatory Skin Diseases](https://www.diabetesincontrol.com/wp-content/uploads/2026/03/glp-1-dermatologic-effects.png)
The Precision Peptide Genetic Test analyzes 14 pathways including stress-response and serotonin-signaling genetics to identify individual vulnerability to mood shifts
![glp-1 skin sensitivity RAs and Health: Exploring Dermatologic Side Effects and Therapeutic Interventions[v1] GLP-1RA & Inflammatory Skin Diseases](https://plexusdx.com/cdn/shop/articles/b6_750d9098-71a8-492b-a1eb-ec8e42cb55a8.jpg?v=1781792624&width=4608)
The incidence of depression or self-harm was 8.2 vs 11.7 events/1,000 person-years in the DPP-4i-cohort and 18.2 vs 13.6 events/1,000 person-years in the GLP-1 RA cohort for incretin-based therapies vs sulfonylureas, respectively